TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optivate in People With Von Willebrand Disease Undergoing Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Have given written informed consent.~2. Be aged 12 years or older.~3. Have VWD of known type.~4. Be due to undergo surgery, in which the investigator believes a VWF concentrate will be required.~5. Have a known lack of, poor response to, or contraindication to, DDAVP, or require a type of surgery in which a plasma-derived product is appropriate.~6. Have a prothrombin time (PT) of not more than 3 seconds above the upper limit of the reference range.~7. Female patients of child-bearing potential, with the exception of pregnant patients undergoing Caesarean surgery or other modes of delivery, including normal vaginal delivery, must have a negative result on a human chorionic gonadotropin-based pregnancy test. If a female patient is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study.~Exclusion Criteria:~1. Have a history of inhibitor development to VWF or FVIII or a positive result at screening (positive screen for VWF inhibitor; positive screen and a result of \>0.5 BU for FVIII inhibitor). A result at screening is not mandatory if the patient is to undergo emergency surgery and the local laboratory is unable to perform the analyses.~2. Patients with thrombocytopenia (platelets \<50 x 109/L).~3. Patients who have clinically significant renal disease (creatinine \>200 µmol/L).~4. Patients who have clinically significant liver disease (ALT levels greater than three times the upper limit of the reference range).~5. Presence of any other major systemic illnesses which would compromise the outcome of the study in the opinion of the investigator.~6. Known or suspected hypersensitivity to investigational medicinal product (IMP) or its excipients.~7. Have a recent history of alcohol or drug abuse.~8. Administration of a new chemical entity within the 4 months preceding enrolment.~9. Participation in any other clinical study in which investigational or marketed drugs were employed in the 30 days preceding enrolment (screening visit) into this study, with the exception of the BPL clinical study Protocol 8VWF01.~10. Female patients who are lactating.~11. In the opinion of the investigator, the patient is unlikely to comply with the study protocol.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Age over 18 years~2. The ability to provide informed consent for enrollment in the study~3. Diagnosis of conjunctival nevus (Group 1 only)~4. Diagnosis of racial melanosis (Group 2 only)~5. Diagnosis or suspicion of primary acquired melanosis (PAM), scheduled for biopsy (Group 3 only)~6. Diagnosis of possible MM scheduled for biopsy (Group 4 only)~7. Confirmed diagnosis of MM based upon clinical and histopathological findings, and have already undergone resection(Group 4 only)~8. Confirmed diagnosis of MM recurrence based upon clinical and histopathological findings(Group 4 only)~9. Clear cornea (Group 5 only)~10. No conjunctival lesions or recent conjunctival diseases(Group 5 only)~11. No recent chemotherapy or radiotherapy(Group 5 only)~Exclusion criteria:~1. History of previous ocular surgery within last 3 months~2. History of inflammatory eye diseases within last 3 months~3. Current or history of glaucoma disease and on glaucoma medication~4. Contact lens use within last 3 months~5. Physical inability to cooperate for confocal microscopy~6. Prior history of infectious keratitis within 3 months~7. Suspicion for PAM or malignant melanoma (MM)(Groups 1,2,3)~8. History of PAM or MM(Groups 1,2,3)~9. Histopathology not confirmatory for MM (group 4 only)~10. History of other ocular carcinoma or any recent ocular topical chemotherapy or radiotherapy (Group 5 only)~11. History of cancer elsewhere in the body which is currently under systemic chemotherapy (group 5 only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nevus (Type: None): None
- Racial Melanosis (Type: None): None
- Primary Acquired Melanosis (Type: None): None
- Malignant Melanoma (Type: None): None
- Normal (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Whole Food, Plant-Based Nutrition on Chronic Kidney Disease With Proteinuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~* Subjects with CKD 3b and 4 (as determined by an estimated glomerular filtration rate of ≥ 15 ml/min but ≤ 45 ml/min for at least three months)~* Subjects with proteinuria documented at least twice with the most recent test within the last 6 months as determined by:~  * Urine albumin excretion rate of \> 300 mg/day or urine albumin to creatinine ratio of \> 300 mg/g of creatinine~ * Urine protein excretion rate of \> 500 mg/day or urine protein to creatinine ratio of \> 0.5 g/g of creatinine~* If using angiotensin converting enzyme inhibitor, angiotensin receptor blockers and/or aldosterone antagonists, on a stable dose of for greater than one month~* Fluent in English language~* Able and willing to comply with the testing and group education schedules~* Able and willing to comply with a whole-food, plant-based diet~* Able and willing to give informed consent~Exclusion Criteria:~* Any kidney disease requiring immunosuppressive therapy~* Pregnancy or intent to become pregnant in the next 12 months~* Life expectancy \< 12 months~* History of solid organ transplant or anticipated solid organ transplant in next 12 months~* History of hyperkalemia: Two potassium measurements \> 5.1 Meq/L within the last three months, or history of any intervention for hyperkalemia in the last 6 months~* Subjects with malabsorptive syndromes~* Subjects with history of bariatric surgery or planned bariatric surgery in the next 12 months~* Subjects on warfarin~* Subjects with current eating disorders~* Subjects with tobacco or illicit substance use~* Subjects with alcohol use of \> 7 drinks per week~* Allergy or intolerance of a plant-based or plant-derived food (gluten, soy, etc.)~* Following a vegan diet in the six months prior to consent~* Major surgery within 60 days prior to consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Subjects in this arm will immediately begin a whole-food, plant-based nutrition program consisting of weekly educational group meetings and prepared meals delivered to the subjects' homes for the first 12 weeks followed by monthly educational group meetings for an additional 6 months.
- Wait List Control (Type: OTHER): Subjects in this arm will continue their usual care as directed by their nephrologist for 12 weeks before starting the same whole-food, plant-based nutrition program as the intervention arm subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Surgery and Radiofrequency for Treatment of Renal Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Solid kidney tumor: diameter \<= 40mm, maximum volume 32cc~* Intra-parenchymatous localization~* At least one of the following criteria:~  * Patient of more than 70 years old~ * Hereditary kidney cancer (von Hippel-Lindau Disease disease, hereditary tubulopapillary carcinoma...)~ * Single kidney, with tumor difficult to reach to a conservative surgery (central-hilar or intra-parenchymatous tumour...)~ * Context of local recurrence after partial kidney surgery~ * Patient with impaired renal function (renal clearance \< 30 ml/min)~* Written informed consent~Exclusion Criteria:~* Conservative surgery feasible in good technical and carcinological conditions~* Contra-indication to either treatment~* Kidney cancer metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Major Patient~2. Patient with a diagnosis of Alzheimer's disease according to DSM-IV and NINCDS-ADRDA criteria.~3. Patient at a moderate stage of the disease: Score at CDR (Clinical Dementia Rating Scale) between 0.5 inclusive and 2 inclusive and MMS score greater than or equal to 10 and lower strictly at 27~4. Lexical-semantic disorder~5. Treatment with pro-cognitive drugs at stable doses for at least 3 months,~6. Speech therapy in progress (2 or 3 sessions per week)~7. Patient with free and informed consent~8. Affiliated to the Health care system~9. Native french speaker,~10. Attendance of a caregiver.~For the early onset group, patients should have started the disease before 65 years of age. The randomization will be stratified according to age (\<65 years or\> 65 years), enabling to include 2 groups of identical size of young AD (Alzheimer Disease) and Late (Alzheimer Disease) patients, each half distributed in the tablet or control group.~Exclusion Criteria:~1. Other known neurological disease or general illness or major psychic problems that may interfere with cognitive functioning,~2. Patient under guardianship or curatorship~3. Confusion,~4. Cerebral MRI (or scanner for contraindication to MRI), obtained in the context of routine care compatible with a pathological process other than that related to Alzheimer's disease. A discrete or moderate leukoaraiosis (stages 1 and 2 of Fazekas) will not be considered as a criterion of non-inclusion.~5. Uncorrected hearing or visual impairment~6. Inclusion in another intervention protocol.~7. Participation in an additional stimulation workshop

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tablet group (Type: EXPERIMENTAL): Patients will continue their usual care (1 or more sessions of weekly speech therapy) and will benefit from the therapy on tablet for 3 months.
- Control group (Type: ACTIVE_COMPARATOR): Patients will continue their usual care (1 or more sessions of weekly speech therapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* soft tissue sarcoma, histologically proven~* tumor size \> 5 cm (SBR grade 2) or whatever size (SBR grade 3)~* complete excision (R0 or R1)~* no metastasis (checked by spiral chest CT)~* social security covered~* informed signed consent~Exclusion Criteria:~* bone, visceral, uterine, retroperitoneal sarcoma~* GIST~* other malignant tumor~* patients over 70, or for whom thoracic surgery is excluded~* pneumoconiosis or known system disease~* breast feeding or pregnant woman~* patient unable to undergo trail medical follow up for geographic, social or psychological reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- chest radiography (Type: ACTIVE_COMPARATOR): clinical exam + chest radiography every 3 months during 2 years and every 6 months during 1 year
- chest CT (Type: ACTIVE_COMPARATOR): clinical exam + Chest CT every 3 months during 2 years and every 6 months during 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with moderate to severe RA for whom the physician had decided to treat with golimumab according to the local product label, with the first dose being administered between 12 and 26 weeks prior to study enrollment~* Participants who have achieved an adequate therapeutic response to regular doses of golimumab, within 12 to 26 weeks of treatment~* Participants should be evaluated for tuberculosis (TB) exposure/risk factors or managed for active and latent TB (per local requirements and according to the local product label)~* Participants who have been evaluated for active/latent hepatitis B virus (HBV) and hepatitis C virus (HCV)~* Participants for whom, since golimumab initiation, a complete medical record is available~Exclusion criteria:~* Participants who have received and terminated golimumab treatment in the past~* Participants that have been treated with golimumab for more than 26 weeks prior to enrolment in the study~* Participants with use of any other investigational agent less than or equal to 30 days before starting treatment with golimumab~* Participants with suspected latent TB, having not received prophylactic treatment of at least 4 weeks~* Participants with suspected or active TB~* Participants with active/latent HBV or HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Golimumab (Type: None): Participants with rheumatoid arthritis in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for 24 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Current major depressive episode of bipolar I or bipolar II disorder, according to DSM-IV TR~* Moderate to severe depression~* History of at least one documented mania or hypomania episode~* Absence of current mania or hypomania~Exclusion Criteria:~* Any current psychiatric disorder other than bipolar disorder defined in the DSM-IV TR~* Any substance disorder with the previous 6 months~* Use of any psychoactive medication (including mood stabilizers) within 2 weeks before randomisation and during the study~* ECT within 6 months before the study~* Female of childbearing potential and not using adequate contraception~Other protocol-defined inclusion and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lu AA34893: 4 mg (Type: EXPERIMENTAL): None
- Lu AA34893: 12 mg (Type: EXPERIMENTAL): None
- Lu AA34893: 18 mg (Type: EXPERIMENTAL): None
- Quetiapine fumarate (Type: OTHER): Active reference 300 mg
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NB as defined by a) histopathology (confirmed by the MSKCC Department of Pathology), or b) BM metastases or MIBG-avid lesion(s) plus high urine catecholamine levels.~* High-risk NB as defined by risk-related treatment guidelines1 and the International NB Staging System,89 i.e., stage 4 with (any age) or without (\> or = to 18 months of age) MYCN amplification, MYCN-amplified stage 2 or stage 3 (any age), or MYCN-amplified stage 4S.~* The patients are in \>2nd CR/VGPR, including no measurable MIBG-avid soft tissue tumor assessable for response.~* Signed informed consent indicating awareness of the investigational nature of this program.~Exclusion Criteria:~* Creatinine \> 3.0 mg/dL~* ALT, AST and Alkaline Phosphatase \> 5.0 times the upper limit of normal~* Bilirubin \> 3.0 mg/dL~* Patients with grade 3 or higher toxicities (using the CTCAE v34.0) related to cardiac, neurological, pulmonary or gastrointestinal function as determined by physical exam. Patients must have normal blood pressure for age.~* Progressive disease~* History of allergy to mouse proteins~* Active life-threatening infection.~* Human anti-mouse antibody (HAMA) titer \>1000 Elisa units/ml.~* Inability to comply with protocol requirements.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid (Type: EXPERIMENTAL): This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neuropsycholgy and Neuroimaging in Transient Global Amnesia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All the participants~  * Minimum of 7 years of education~ * French native speaker~* Healthy subjects : Non pathological Dementia rating scale score~* Patients : Clinical diagnosis of TGA according to Hodges and Warlow's criterion~Exclusion Criteria:~* Chronic neurological disease~* Encephalitis~* Endocrinal disease~* Hepatic disease~* Case history of head injury with loss of consciousness of more than one hour~* Case history of stroke~* Case history of cancer during the five last years except squamous cell carcinomas~* Alcoholism or drug addiction~* Major psychiatric disorders according the Diagnostic and Statistical Manual of -Mental Disorders

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- TGA (Type: EXPERIMENTAL): None
- Controls (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aiberry AI Mental Health Screening Platform

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 13 to 79 years old~* English-speaking~Exclusion Criteria:~* Previous participant in the study, within the last three months~* Individuals unable to verbally respond to standardized questions~* Individuals unable to participate in a virtual visit as they do not have the right hardware (phone/laptop) or no internet connectivity~* Individuals unable to provide consent

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility